Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
Source: SeekingAlpha
2026-02-05 17:35:23 ET
More on Haemonetics
- Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
- Haemonetics Corporation 2026 Q3 - Results - Earnings Call Presentation
- Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Haemonetics Q3 2026 Earnings Preview
- Haemonetics acquires Vivasure Medical
Read the full article on Seeking Alpha
For further details see:
Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
Haemonetics Corporation
NASDAQ: HAE
HAE Trading
-3.23% G/L:
$62.26 Last:
348,802 Volume:
$63.98 Open:
HAE Latest News
February 23, 2026 04:15:00 pm
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
February 20, 2026 04:05:00 pm
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
HAE Stock Data
$2,748,315,639
45,616,277
0.08%
124
N/A
Medical Equipment & Supplies
Healthcare
US
Boston
